{"blog": [], "keywords": [{"value": "Clinical Trials", "name": "subject", "rank": "1", "is_major": "N"}, {"value": "Lung Cancer", "name": "subject", "rank": "2", "is_major": "Y"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "3", "is_major": "Y"}, {"value": "Bristol Myers Squibb Company", "name": "organizations", "rank": "4", "is_major": "Y"}, {"value": "Merck & Company Inc", "name": "organizations", "rank": "5", "is_major": "Y"}], "web_url": "http://www.nytimes.com/2016/08/06/business/lung-cancer-drug-opdivo-fails-clinical-trial-to-expand-use.html", "document_type": "article", "byline": {"person": [{"lastname": "POLLACK", "firstname": "Andrew", "role": "reported", "organization": "", "rank": 1}], "original": "By ANDREW POLLACK"}, "type_of_material": "News", "multimedia": [{"url": "images/2016/08/06/business/06DRUG/06DRUG-thumbWide.jpg", "legacy": {"wide": "images/2016/08/06/business/06DRUG/06DRUG-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/08/06/business/06DRUG/06DRUG-articleLarge.jpg", "legacy": {"xlarge": "images/2016/08/06/business/06DRUG/06DRUG-articleLarge.jpg", "xlargeheight": "401", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 401}, {"url": "images/2016/08/06/business/06DRUG/06DRUG-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/08/06/business/06DRUG/06DRUG-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "1045", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "Bristol-Myers Squibb said the drug had not slowed the progression of advanced lung cancer in a test seeking approval to use it as an initial treatment.", "pub_date": "2016-08-05T15:59:16+0000", "news_desk": "Business", "headline": {"print_headline": "Immunotherapy Drug Fails Lung Cancer Trial", "main": "Immunotherapy Drug Opdivo Fails Clinical Trial to Expand Use"}, "print_page": "1", "snippet": "Bristol-Myers Squibb said the drug had not slowed the progression of advanced lung cancer in a test seeking approval to use it as an initial treatment....", "_id": "57aa084f95d0e021d797ee8d", "slideshow_credits": null, "abstract": "Bristol-Myers Squibb says its best-selling immunotherapy drug Opdivo failed as initial treatment for lung cancer in clinical trial; announcement plunges manufacturer's shares 16 percent and raises value of shares of rival Merck, makers of Keytruda, immunotherapy medication that succeeded in similar clinical trial."}